Sugi Predict

Sugi Predict / Compounds / SCHEMBL5581546

SCHEMBL5581546

SCHEMBL5581546

CC(C)C[C@H](NC(=O)c1cc2ccccc2n1C)C(=O)N[C@@H]1CCCN(S(=O)(=O)c2ccccc2C#N)CC1

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 9/20 0.48
▸ CTSS P25774 5/20 0.48
▸ CTSK P43235 8/20 0.41
▸ CTSB P07858 3/20 0.41
▸ CTSV O60911 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ TRPA1 O75762 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ UTS2R Q9UKP6 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29590366 1.00 CTSL (0.48) CTSLCTSSCTSKCTSBCTSV
SCHEMBL14342619 1.00 CTSL (0.48) CTSLCTSSCTSKCTSBCTSV
SCHEMBL14366322 0.94 CTSL (0.41) CTSLCTSSCTSKCTSBCTSV
SCHEMBL14362854 0.89 CTSL (0.44) CTSLCTSSCTSKCTSBCTSV
SCHEMBL4037337 0.89 CTSK (0.54) CTSLCTSSCTSKCTSBCTSV
SCHEMBL461847 0.89 CTSK (0.54) CTSLCTSSCTSKCTSBCTSV
SCHEMBL14342661 0.86 CTSL (0.43) CTSLCTSSCTSKCTSBCTSV
SCHEMBL4072175 0.86 CTSL (0.43) CTSLCTSSCTSKCTSBCTSV
SCHEMBL4075417 0.85 KDM4E (0.45) CTSLCTSSCTSKPOLBATM
SCHEMBL14342647 0.85 F10 (0.45) CTSLCTSSCTSKCTSBCTSV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160303139-A1 TARGETING PRIMARY CILIA TO TREAT GLAUCOMA UNIV INDIANA RES & TECH CORP (US) 2016-10-20 — — US claimed
US-20150231148-A1 TARGETING PRIMARY CILIA TO TREAT GLAUCOMA NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-08-20 — — US claimed
US-20130203715-A1 USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS PULMATRIX, INC. (US) 2013-08-08 — — US claimed
US-20240156728-A1 MONOVALENT METAL CATION DRY POWDERS FOR INHALATION PULMATRIX OPERATING CO INC (US) 2024-05-16 — — US disclosed
EP-4008326-A1 MONOVALENT METAL CATION DRY POWDERS FOR INHALATION Pulmatrix Operating Company, Inc. (US) 2022-06-08 — — EP disclosed
US-11173115-B2 Monovalent metal cation dry powders for inhalation PULMATRIX OPERATING COMPANY, INC. (US) 2021-11-16 — — US disclosed
EP-3470057-B1 CATIONIC DRY POWDERS COMPRISING MAGNESIUM SALT PULMATRIX OPERATING CO INC (US) 2021-11-03 — — EP disclosed
US-20210121399-A1 MONOVALENT METAL CATION DRY POWDERS FOR INHALATION PULMATRIX OPERATING COMPANY, INC. 2021-04-29 — — US disclosed
US-10806871-B2 Inhalable dry powders PULMATRIX OPERATING COMPANY, INC. (US) 2020-10-20 — — US disclosed
US-20200261667-A1 INHALABLE DRY POWDERS PULMATRIX OPERATING COMPANY, INC. 2020-08-20 — — US disclosed
US-10589039-B2 Methods for producing respirable dry powders Pulmatric Operating Company, Inc. (US) 2020-03-17 — — US disclosed
US-20150231066-A1 MONOVALENT METAL CATION DRY POWDERS FOR INHALATION PULMATRIX, INC. (US) 2015-08-20 — — US disclosed
US-20150136130-A1 INHALABLE DRY POWDERS PULMATRIX, INC. 2015-05-21 — — US disclosed
US-20140336159-A1 METHODS FOR TREATING AND DIAGNOSING RESPIRATORY TRACT INFECTIONS PULMATRIX, INC. 2014-11-13 — — US disclosed
US-20130266653-A1 MONOVALENT METAL CATION DRY POWDERS FOR INHALATION PULMATRIX, INC. (US) 2013-10-10 — — US disclosed
US-20130243828-A1 CATIONIC DRY POWDERS PULMATRIX, INC. (US) 2013-09-19 — — US disclosed
US-20130203715-A1 USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS PULMATRIX, INC. (US) 2013-08-08 — — US disclosed
US-20070293477-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION 2007-12-20 — — US disclosed
US-20070293477-A1 Novel Compounds SMITHKLINE BEECHAM CORPORATION 2007-12-20 — — US disclosed
US-20070259856-A1 Method for Activating Trpv4 Channel Receptors by Agonists SMITHKLINE BEECHAM CORPORATION 2007-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130266653-A1 MONOVALENT METAL CATION DRY POWDERS FOR INHALATION KCNN1, KCNN3, KCNN2 CTSL 3379/4885CTSS 2619/4885CTSK 2112/4885
US-20140336159-A1 METHODS FOR TREATING AND DIAGNOSING RESPIRATORY TRACT INFECTIONS TLR3, TLR1, TLR4 CTSL 82/4885CTSS 365/4885CTSK 380/4885
US-20070259856-A1 Method for Activating Trpv4 Channel Receptors by Agonists TRPV4, TRPV2, TRPV3 CTSL 718/4885CTSS 492/4885CTSK 410/4885
US-20150231066-A1 MONOVALENT METAL CATION DRY POWDERS FOR INHALATION KCNN1, KCNN3, KCNN2 CTSL 3379/4885CTSS 2619/4885CTSK 2112/4885
US-20130203715-A1 USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS TRPV1, TRPC4, TRPC3 CTSL 593/4885CTSS 787/4885CTSK 731/4885
US-20130243828-A1 CATIONIC DRY POWDERS CA2, ORAI1, TRPV5 CTSL 463/4885CTSS 373/4885CTSK 446/4885
US-20070293477-A1 Novel Compounds HRH4, TRPV4, TRPC4 CTSL 1118/4885CTSS 1770/4885CTSK 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.